1
|
Qi P, Li P, Qiao L, Xue H, Ma Y, Wei S, Yang X, Zhang H, Zhang Y, Wang Y, He S, Quan H, Zhang W. Simultaneous quantification of pirarubicin, doxorubicin, cyclophosphamide, and vincristine in human plasma of patients with non-Hodgkin's lymphoma by LC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1224:123754. [PMID: 37229818 DOI: 10.1016/j.jchromb.2023.123754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 05/05/2023] [Accepted: 05/11/2023] [Indexed: 05/27/2023]
Abstract
Pirarubicin (THP), doxorubicin (DOX), cyclophosphamide (CTX), and vincristine (VCR) are widely used in the treatment of patients with non-Hodgkin's Lymphoma. Herein, a precise and sensitive method was developed for the determination of THP, DOX, CTX and VCR in human plasma by high-performance liquid-chromatography-tandem mass spectrometry (LC-MS/MS). Liquid-liquid extraction was applied to extract THP, DOX, CTX, VCR, and the internal standard (IS, Pioglitazone) in plasma. Agilent Eclipse XDB-C18 (3.0 mm × 100 mm) was utilized and chromatographic separation was obtained in eight minutes. Mobile phases were composed of methanol and buffer (10 mM ammonium formate containing 0.1% formic acid). The method was linear within the concentration range of 1-500 ng/mL for THP, 2-1000 ng/mL for DOX, 2.5-1250 ng/mL for CTX, and 3-1500 ng/mL for VCR. The intra- and inter-day precisions of QC samples were found to be below 9.31 and 13.66%, and accuracy ranged from -0.2 to 9.07%, respectively. THP, DOX, CTX, VCR and the internal standard were stable in several conditions. Finally, this method was successfully utilized to simultaneously determine THP, DOX, CTX and VCR in human plasma of 15 patients with non-Hodgkin's Lymphoma after intravenous administration. Finally, the method was successfully employed in the clinical determination of THP, DOX, CTX, and VCR in patients with non-Hodgkin lymphoma after administration of RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens.
Collapse
Affiliation(s)
- Peng Qi
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China; Ningxia Medical University School of Pharmacy, Ningxia, China.
| | - Ping Li
- Cancer Hospital, General Hospital of Ningxia Medical University, Ningxia, China.
| | - Lijiao Qiao
- Cancer Hospital, General Hospital of Ningxia Medical University, Ningxia, China
| | - Huaqian Xue
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China; Ningxia Medical University School of Pharmacy, Ningxia, China
| | - Yanni Ma
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Shijie Wei
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Xiaoying Yang
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Hao Zhang
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Yuxin Zhang
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Yifan Wang
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China; Ningxia Medical University School of Pharmacy, Ningxia, China
| | - Shaolong He
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China
| | - Hongfeng Quan
- Ningxia Medical University School of Pharmacy, Ningxia, China
| | - Wenping Zhang
- Institute of Clinical Pharmacology, Department of Pharmacy, General Hospital of Ningxia Medical University, Ningxia, China.
| |
Collapse
|
2
|
Paziewska−Nowak A, Jankowska−Śliwińska J, Dawgul M, Pijanowska DG. Selective Electrochemical Detection of Pirarubicin by Means of DNA-modified Graphite Biosensor. ELECTROANAL 2017. [DOI: 10.1002/elan.201700067] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Agnieszka Paziewska−Nowak
- Nalecz Institute of Biocybernetics and Biomedical Engineering; PAS; Trojdena St. 4 02-109 Warsaw Poland
| | | | - Marek Dawgul
- Nalecz Institute of Biocybernetics and Biomedical Engineering; PAS; Trojdena St. 4 02-109 Warsaw Poland
| | - Dorota G. Pijanowska
- Nalecz Institute of Biocybernetics and Biomedical Engineering; PAS; Trojdena St. 4 02-109 Warsaw Poland
| |
Collapse
|
3
|
Yang X, Gao H, Qian F, Zhao C, Liao X. Internal standard method for the measurement of doxorubicin and daunorubicin by capillary electrophoresis with in-column double optical-fiber LED-induced fluorescence detection. J Pharm Biomed Anal 2015; 117:118-24. [PMID: 26350558 DOI: 10.1016/j.jpba.2015.08.037] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 08/25/2015] [Accepted: 08/27/2015] [Indexed: 11/17/2022]
Abstract
An internal standard method has been developed for the simultaneous determination of anthracycline antibiotics, doxorubicin (DOX) and daunorubicin (DAN), in rabbit plasma using capillary electrophoresis (CE) with in-column double optical-fiber LED-induced fluorescence detection (CE-ICDOF-LED-FLD). Rhodamine B (RhB) was selected as an internal standard because its emission wavelength is similar to that of the anthracycline antibiotics. Parameters including buffer pH, buffer concentration, organic solvents and separation voltage have been investigated to explore the sensitivity and separation efficiency of DOX and DAN. The optimal electrophoretic separation conditions were a borate buffer (15 mM, pH 9.0) containing 50% acetonitrile (v/v), 10 s hydrodynamic injection at a height of 20 cm and a separation voltage of 15 kV. The developed CE-ICDOF-LED-FLD method provides limits of detection of 18 and 13 ng/mL for DOX and DAN in rabbit plasma samples, respectively. The recoveries ranging from 93.7 to 104.8% and the relative standard deviations at 1.1-1.7% were achieved for DOX and DAN in spiked rabbit plasma samples.
Collapse
Affiliation(s)
- Xiupei Yang
- College of Chemistry and Chemical Engineering, Chemical Synthesis and Pollution Control Key Laboratory of Sichuan Province, China West Normal University, Nanchong 637000, PR China.
| | - Huanhuan Gao
- College of Chemistry and Chemical Engineering, Chemical Synthesis and Pollution Control Key Laboratory of Sichuan Province, China West Normal University, Nanchong 637000, PR China
| | - Fan Qian
- College of Chemistry and Chemical Engineering, Chemical Synthesis and Pollution Control Key Laboratory of Sichuan Province, China West Normal University, Nanchong 637000, PR China
| | - Chuan Zhao
- College of Chemistry and Chemical Engineering, Chemical Synthesis and Pollution Control Key Laboratory of Sichuan Province, China West Normal University, Nanchong 637000, PR China
| | - Xiangjun Liao
- Exposure and Biomonitoring Division, Health Canada, 50Colombine Driveway, Ottawa K1A 0K9, Canada.
| |
Collapse
|
4
|
Glutathione-s-transferase modified electrodes for detecting anticancer drugs. Biosens Bioelectron 2014; 58:232-6. [DOI: 10.1016/j.bios.2014.02.070] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2013] [Revised: 02/23/2014] [Accepted: 02/25/2014] [Indexed: 12/12/2022]
|
5
|
Electrochemical Reduction and Voltammetric Determination of Pirarubicin at Carboxyl Ions Implantation-Modified Indium Tin Oxide Electrode. CHINESE JOURNAL OF ANALYTICAL CHEMISTRY 2011. [DOI: 10.1016/s1872-2040(10)60454-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Maudens KE, Stove CP, Lambert WE. Optimization of a liquid chromatographic separation for the simultaneous determination of four anthracyclines and their respective 13-S
-dihydro metabolites. J Sep Sci 2008; 31:1042-9. [DOI: 10.1002/jssc.200700490] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
7
|
Emara S, Morita I, Tamura K, Razee S, Masujima T, Mohamed HA, Gizawy SME, Rabbat NAE. Utility of Ion-Pair Chromatography for Analysis of Some Anthracyclines in Plasma and Urine. J LIQ CHROMATOGR R T 2006. [DOI: 10.1080/10826079808005850] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Samy Emara
- a Faculty of Pharmacy Assiut University , Assiut, Egypt
| | - Ikue Morita
- b Institute of Pharmaceutical Sciences School of Medicine , Hiroshima University , 1-2-3 Kasumi, Minami-ku, Hiroshima, 734, Japan
| | - Keiko Tamura
- b Institute of Pharmaceutical Sciences School of Medicine , Hiroshima University , 1-2-3 Kasumi, Minami-ku, Hiroshima, 734, Japan
| | - Saeid Razee
- b Institute of Pharmaceutical Sciences School of Medicine , Hiroshima University , 1-2-3 Kasumi, Minami-ku, Hiroshima, 734, Japan
| | - Tsutomu Masujima
- b Institute of Pharmaceutical Sciences School of Medicine , Hiroshima University , 1-2-3 Kasumi, Minami-ku, Hiroshima, 734, Japan
| | | | | | | |
Collapse
|
8
|
Chen CL, Thoen KK, Uckun FM. High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 764:81-119. [PMID: 11817045 DOI: 10.1016/s0378-4347(01)00314-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Various methods for separating eleven different types of topoisomerase II (TOPO-2) inhibitors, including epipodophyllotoxins, anthracyclines, anthracenediones, anthrapyrazoles, anthracenebishydrazones, indole derivatives, aminoacridines, benzisoquinolinediones, isoflavones, bisdioxopiperazines and thiobarbituric acids, are summarized. Proper sample preparation and storage is critical to the successful analysis of some TOPO-2 inhibitors due to difficulties associated with adsorption, instability and complex biological components. Solid-phase and liquid-liquid extractions are widely used to separate TOPO-2 inhibitors from biological samples, although simple deproteinization followed by direct analysis of the supernatant is preferable to extraction based on its speed and simplicity. High-performance liquid chromatography (HPLC) is the favored method for the bioanalysis of TOPO-2 inhibitors. UV or diode array detection is generally employed for early pharmacokinetic studies, while fluorescence or electrochemical detection is used more frequently for analytes with fluorescent or oxidative-reductive properties. For analyses requiring highly sensitive and/or specific detection, electrospray mass spectrometry (ESI-MS or ESI-MS-MS) provides a suitable alternative. A comprehensive compilation of the HPLC techniques currently used to separate TOPO-2 inhibitors will aid the future development of analytical methods for new TOPO-2 inhibitors.
Collapse
Affiliation(s)
- C L Chen
- Department of Pharmaceutical Sciences, Parker Hughes Cancer Center, Parker Hughes Institute, St. Paul, MN 55113, USA
| | | | | |
Collapse
|
9
|
Rousseau A, Marquet P, Debord J, Sabot C, Lachâtre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38:315-53. [PMID: 10803455 DOI: 10.2165/00003088-200038040-00003] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Numerous studies have found a clear relationship between systemic exposure and the toxicity or (more rarely) the efficacy of anticancer agents. Moreover, the clearance of most of these drugs differs widely between patients. These findings, combined with the narrow therapeutic index of anticancer drugs, suggest that patient outcome would be improved if doses were individualised to achieve a target systemic exposure. Bayesian maximum a posteriori probability (MAP) forecasting is an efficient and robust method for the optimisation of drug therapy, but its use for anticancer drugs is not yet extensive. The aim of this paper is to review the application of population pharmacokinetics and MAP to anticancer drugs and to evaluate whether and when MAP Bayesian estimation improves the clinical benefit of anticancer chemotherapy. For each drug, the relationships between pharmacokinetic variables [e.g. plasma concentration or the area under the concentration-time curve] and pharmacodynamic effects are described. Secondly, the methodologies employed are considered and, finally, the results are analysed in terms of predictive performance as well as, where possible, the impact on clinical end-points. Some studies were retrospective and intended only to evaluate individual pharmacokinetic parameter values using very few blood samples. Among the prospective trials, a few studied the pharmacokinetic/pharmacodynamic relationships which provided the basis for routine pharmacokinetic monitoring. Others were performed in clinical context where MAP Bayesian estimation was used to determine maximum tolerated systemic exposure (e.g. for carboplatin, topotecan, teniposide) or for pharmacokinetic monitoring (e.g. for methotrexate or platinum compounds). Indeed, its flexibility in blood sampling times makes this technique much more applicable than other limited sampling strategies. These examples demonstrate that individual dose adjustment helps manage toxicity. The performance of pharmacokinetic monitoring is linked to the methodology used at each step of its design and application. Moreover, a limitation to the use of pharmacokinetic monitoring for certain anticancer drugs has been the difficulty in obtaining pharmacokinetic or pharmacodynamic data. Recent progress in analytical methods, as well as the development of noninvasive methods (such as positron emission tomography) for evaluating the effects of chemotherapy, will help to define pharmacokinetic-pharmacodynamic relationships. Bayesian estimation is the strategy of choice for performing pharmacokinetic studies, as well as ensuring that a given patient benefits from the desired systemic exposure. Together, these methods could contribute to improving cancer chemotherapy in terms of patient outcome and survival.
Collapse
Affiliation(s)
- A Rousseau
- Department of Pharmacology and Toxicology, University Hospital, Limoges, France.
| | | | | | | | | |
Collapse
|
10
|
Lachâtre F, Marquet P, Ragot S, Gaulier JM, Cardot P, Dupuy JL. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2000; 738:281-91. [PMID: 10718646 DOI: 10.1016/s0378-4347(99)00529-0] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A sensitive and very specific method, using liquid chromatography-electrospray mass spectrometry (LC-ES-MS), was developed for the determination of epirubicin, doxorubicin, daunorubicin, idarubicin and the respective active metabolites of the last three, namely doxorubicinol, daunorubicinol and idarubicinol in human serum, using aclarubicin as internal standard. Once thawed, 0.5-ml serum samples underwent an automated solid-phase extraction, using C18 Bond Elut cartridges (Varian) and a Zymark Rapid-Trace robot. After elution of the compounds with chloroform-2-propanol (4:1, v/v) and evaporation, the residue was reconstituted with a mixture of 5 mM ammonium formate buffer (pH 4.5)-acetonitrile (60:40, v/v). The chromatographic separation was performed using a Symmetry C18, 3.5 microm (150 x 1 mm I.D.) reversed-phase column, and a mixture of 5 mM ammonium formate buffer (pH 3)-acetonitrile (70:30, v/v) as mobile phase, delivered at 50 microl/min. The compounds were detected in the selected ion monitoring mode using, as quantitation ions, m/z 291 for idarubicin and idarubicinol, m/z 321 for daunorubicin and daunorubicinol, m/z 361 for epirubicin and doxorubicin, m/z 363 for doxorubicinol and m/z 812 for aclarubicin (I.S.). Extraction recovery was between 71 and 105% depending on compounds and concentration. The limit of detection was 0.5 ng/ml for daunorubicin and idarubicinol, 1 ng/ml for doxorubicin, epirubicin and idarubicin, 2 ng/ml for daunorubicinol and 2.5 ng/ml for doxorubicinol. The limit of quantitation (LOQ) was 2.5 ng/ml for doxorubicin, epirubicin and daunorubicinol, and 5 ng/ml for daunorubicin, idarubicin, doxorubicinol and idarubicinol. Linearity was verified from these LOQs up to 2000 ng/ml for the parent drugs (r > or = 0.992) and 200 ng/ml for the active metabolites (r > or = 0.985). Above LOQ, the within-day and between-day precision relative standard deviation values were all less than 15%. This assay was applied successfully to the analysis of human serum samples collected in patients administered doxorubicin or daunorubicin intravenously. This method is rapid, reliable, allows an easy sample preparation owing to the automated extraction and a high selectivity owing to MS detection.
Collapse
Affiliation(s)
- F Lachâtre
- Department of Pharmacology and Toxicology, University Hospital, Limoges, France
| | | | | | | | | | | |
Collapse
|
11
|
Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C, Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit 1999; 21:367-75. [PMID: 10365655 DOI: 10.1097/00007691-199906000-00022] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A single high-performance liquid chromatography (HPLC) method, suitable for the analysis of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites is validated in the present study. Preparation of plasma samples was performed by a first extraction of analytes with a chloroform/1-heptanol mixture (9:1) and reextraction with ortophosphoric acid 0.1 M. The chromatographic analysis was carried out by reversed-phase isocratic elution of anthracyclines with a Supelcosil LC-CN 5 mm column (25 cm x 4.6 mm internal diameter; Supelco) and detection was accomplished by spectrofluorimetry at excitation and emission wavelengths of 480 and 560 nm, respectively. All anthracyclines eluted within 15 minutes of injection and the method appeared to be specific, because the chromatographic assay did not show interferences at the retention time of analytes. The linearity, evaluated over a concentration range of 0.4-10,000 ng/mL, gave regression coefficients better than 0.999, with recoveries of doxorubicin-doxorubicinol and epirubicin-epirubicinol of 67%-109% and 61%-109% respectively, and 93%-109% for the other compounds. The limits of detection and quantification were 0.4 ng/mL in a 50-mL sample (40 pg/injection) for all anthracyclines tested. The method proved to be precise and accurate, as the within-day and between-day coefficients of variation were less than 10% and the accuracy of the assay was in the range of 91%-107%. Overall results indicate that it is feasible to analyze all the anthracyclines used in clinical practice and their major metabolites with a single optimized method, thereby simplifying their monitoring in chemotherapeutic regimens of cancer patients.
Collapse
Affiliation(s)
- S Fogli
- Department of Oncology, University of Pisa, Italy
| | | | | | | | | | | | | |
Collapse
|
12
|
Alvarez-Cedrón L, Sayalero ML, Lanao JM. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1999; 721:271-8. [PMID: 10052699 DOI: 10.1016/s0378-4347(98)00475-7] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A specific and selective high-performance liquid chromatography (HPLC) technique that requires few manipulations, and is readily adaptable to analysis for a large series of samples, has been developed for the determination of the concentration of the anticancer drug doxorubicin (DXR) in rat serum and tissues. The biological samples were efficiently deproteinised and resolved from a reversed-phase nucleosil C18 column with fluorescence detection. The validation study of the proposed method was successfully carried out in an assay range of between 5 and 5000 ng/ml and was subsequently implemented in a pharmacokinetic study of DXR in Wistar rats that were treated by intravenous administration of the drug.
Collapse
Affiliation(s)
- L Alvarez-Cedrón
- Department of Pharmacy and Pharmaceutical Technology, University of Salamanca, Spain
| | | | | |
Collapse
|
13
|
Hempel G, Schulze-Westhoff P, Flege S, Laubrock N, Boos J. Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. Electrophoresis 1998; 19:2939-43. [PMID: 9870393 DOI: 10.1002/elps.1150191624] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
A method for the determination of doxorubicin and its main metabolite doxorubicinol in human plasma is described. Two different sample preparation procedures are applied depending on the expected concentration: To monitor the peak plasma levels, 10 microL of plasma are deproteinated with acetonitrile. After centrifugation, the supernatant is directly applied to the capillary by hydrodynamic injection. For the determination of lower amounts of doxorubicin and its main metabolite doxorubicinol 100 microL of plasma is extracted by liquid-/liquid extraction with chloroform. After evaporation of the organic phase, the sample is reconstituted in acetonitrile/water (95/5 v/v) and injected into the capillary by electrokinetic injection. Idarubicin serves as the internal standard. Laser-induced fluorescence detection with an Ar-ion laser emitting at 488 nm and a 520 nm cut-off filter is used for detection. The accuracy of the method was calculated to be 3.0% at higher concentrations and 15.0% at the limit of quantification. Reproducibility data are in accordance to the generally accepted criteria for bioanalytical methods. The limit of quantification is 2 microg/L, enabling us to monitor doxorubicin plasma levels for several days after application. Noninvasive blood sampling (from the fingertip) using heparinized capillaries was found to be a simple and convenient procedure and provides reproducible data. Initial results show high interindividual variability in doxorubicin peak plasma levels.
Collapse
Affiliation(s)
- G Hempel
- Universitäts-Kinderklinik, Abt. Hämatologie/Onkologie, Münster, Germany.
| | | | | | | | | |
Collapse
|
14
|
Amitai Y, Bhooma T, Frischer H. Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes. THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE 1996; 127:588-98. [PMID: 8648264 DOI: 10.1016/s0022-2143(96)90150-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Recognition and analysis of distinct mechanisms by which primaquine and other hemolytic drugs activate the hexose monophosphate shunt (HMS) have suggested a hitherto unsuspected pharmacogenetic interaction between daunorubicin metabolism and glucose-6-phosphate dehydrogenase (G6PD) deficiency. Because this deficiency is very common, and because anthracyclines are indispensable antitumor antibiotics that are biotransformed mainly by carbonyl reductase, we have compared the reductase-mediated conversion of daunorubicin to daunorubicinol and the conversion of doxorubicin to doxorubicinol in G6PD-deficient and nondeficient erythrocytes. We found that even without G6PD deficiency, the HMS dehydrogenases selectively limited daunorubicin metabolism, as contrasted with that of doxorubicin. The milder GdA- variety of G6PD deficiency restricted the biotransformation of daunorubicin at therapeutic levels, in hemolysates and intact erythrocytes, within 15 minutes, for at least 24 hours. The bioconversion defect was even more severe in Gd Mediterranean G6PD deficiency. Primaquine aldehyde competed with daunorubicin as a substrate for carbonyl reductase. These studies show that HMS dehydrogenase activity controls carbonyl reductase-dependent biotransformation. New issues arise concerning possible effects of G6PD deficiency on the oncolytic and toxic properties of anthracyclines that are effective substrates for carbonyl reductase and also on non-xenobiotic reactions catalyzed by this enzyme.
Collapse
Affiliation(s)
- Y Amitai
- Department of Pharmacology, Rush-Presbyterian-St. Luke's Medical Center, Rush University, Chicago, IL 60612, USA
| | | | | |
Collapse
|
15
|
Edno L, Bressolle F, Combe B, Galtier M. A reproducible and rapid HPLC assay for quantitation of piroxicam in plasma. J Pharm Biomed Anal 1995; 13:785-9. [PMID: 7669833 DOI: 10.1016/0731-7085(95)01289-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- L Edno
- Laboratoire de Pharmacocinétique, Hôpital Carémeau, Nîmes, France
| | | | | | | |
Collapse
|
16
|
Marchiset-Leca D, Leca FR, Galeani A, Noble A, Catalin J. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics. Cancer Chemother Pharmacol 1995; 36:239-43. [PMID: 7781145 DOI: 10.1007/bf00685853] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The pharmacokinetic monitoring of anthracycline-containing regimens is warranted because of the important toxicity of these drugs and because pharmacokinetic-pharmacodynamic relationships have been clearly established. We studied the pharmacokinetics of the new anthracycline pirarubicin in 80 courses of treatment performed in 27 patients, using a limited sampling protocol we had previously validated. We observed (for 47 of these courses) a significant correlation between the leucocyte cell kill and the pirarubicin area under the time x concentration curve, but the most significant correlation was obtained using the plasma concentration of doxorubicin, a metabolite of pirarubicin, at the end of the infusion. On the basis of this value, it is possible to predict for pirarubicin haematological toxicity in a way that can help the clinician in identifying patients at risk for toxicity.
Collapse
Affiliation(s)
- D Marchiset-Leca
- Laboratoire de Pharmacocinétique, Centre Hospitalier Départemental de Castelluccio, Ajaccio, France
| | | | | | | | | |
Collapse
|
17
|
Bressolle F, Jacquet JM, Galtier M, Jourdan J, Donadio D, Rossi JF. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol 1992; 30:215-8. [PMID: 1628370 DOI: 10.1007/bf00686315] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography with fluorescence detection. As reported previously, a wide range of plasma levels were found among our patients. It appears that in addition to being quickly cleared from the plasma, both DOX and DOXol are excreted in detectable amounts in parotid saliva, a route of elimination that has been given little attention, if any. Excretion in the saliva exposes the mucosa of the upper gastrointestinal tract to drug and may play a role in causing stomatitis in patients receiving DOX by the i.v. route. Since huge interindividual and pronounced intraindividual differences were found in S/P ratios that mostly were not systematically related to the plasma drug concentration, the concentration in parotid saliva was not useful in predicting the level of free DOX and DOXol in plasma. For the parent drug and its metabolite, the S/P ratios increased significantly with time during the 48-h period after dosing.
Collapse
Affiliation(s)
- F Bressolle
- Département de Pharmacocinétique, Faculté de Pharmacie, Montpellier, France
| | | | | | | | | | | |
Collapse
|